^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMA401

    i
    Other names: IMA401
    Associations

    News

    Trials
    Company:
    BMS, Immatics
    Drug class:
    TCR modulator, MAGE-A4 inhibitor, MAGE-A8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, Immatics Biotechnologies GmbH | Phase classification: P1a/1b --> P1
    Phase classification
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression • MAGEA4 overexpression
    |
    IMA401
    2years
    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=50, Recruiting, Immatics Biotechnologies GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression
    |
    IMA401
    2years
    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=50, Not yet recruiting, Immatics Biotechnologies GmbH
    New P1 trial
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression
    |
    IMA401